InflaRx NV of Germany has raised a net $57.1 million from a primary and secondary offering of its shares on Nasdaq to support its portfolio of drugs for inflammatory diseases that target the complement system, a component of the innate immune system.
Takeda Pharmaceutical Company Ltd has won the agreement of Shire Plc to a takeover that values the Ireland-based company at $62 billion and will potentially strengthen Takeda’s position in the US. Although headquartered in Dublin, Shire generates most of its business from the US.
The UK gene therapy company Autolus Ltd has filed papers with the US Securities and Exchange Commission for a proposed initial public offering of its shares on Nasdaq. The offering will take the form of American Depositary Shares each representing one ordinary share in the company.
The UK cancer vaccine company Scancell Holdings Plc has raised £8.7 million from existing and new shareholders in order to advance its portfolio of early clinical stage vaccines for melanoma, non-small cell lung cancer and other solid tumours.
e-Therapeutics Plc aims to identify intervention strategies for the potential treatment of Parkinson’s disease under a new collaboration with the drug discovery company C4X Discovery Holdings Plc.
Crescendo Biologics Ltd has secured $70 million in a Series B financing round to advance its lead product into the clinic for a cancer indication and further develop its pipeline of biologics that are based on a variable domain of the human antibody.
The Wellcome Trust has awarded £4.3 million to PredictImmune of Cambridge UK to finance a clinical trial of the company’s prognostic biomarker test for Crohn’s disease. The assay was developed by researchers at the University of Cambridge.
Shire Plc has secured additional time from the UK competition authority to review a proposed bid from Takeda Pharmaceutical Company Ltd that values the Dublin-based company at £46 billion. The parties have until 8 May to reach a decision.
Shire Plc announced on 16 April that it has reached a deal to sell its oncology business to Servier SAS of France for $2.4 billion. The transaction was described by the company as a move to sharpen its focus on its portfolio for drugs treating rare diseases.
The Belgium-based cell therapy company Promethera Biosciences SA has branched out into biologics with the acquisition of Baliopharm AG, a Swiss developer of therapies for immune-mediated inflammatory diseases and cancer. Financial details of the transaction were not disclosed.